The forecasted Renin-Angiotensin System (RAS) medicine sales in Australia from 2024 to 2028 show a steady, albeit modest, increase in US Dollars per capita. The sales, starting at 22.7 in 2024, gradually grow to 23.3 by 2028. Comparing from previous actuals, the sales stood at 22.6 in 2023, showcasing minimal year-on-year percentage variations: about a 0.44% increase from 2023 to 2024, 0.44% from 2024 to 2025, 0.88% from 2025 to 2026, 0.43% from 2026 to 2027, and 0.87% from 2027 to 2028. The Compound Annual Growth Rate (CAGR) over the 5-year period is approximately 0.62% per year.
Future trends to watch for include potential advancements in RAS therapy technology, influencing prescription rates and pricing strategies. Additionally, healthcare policies and an aging population may drive further increases in demand. Close monitoring of external factors such as economic shifts and healthcare reforms will be essential for a comprehensive market understanding.
